Your browser doesn't support javascript.
loading
Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.
Clerbaux, Laure-Alix; Albertini, Maria Cristina; Amigó, Núria; Beronius, Anna; Bezemer, Gillina F G; Coecke, Sandra; Daskalopoulos, Evangelos P; Del Giudice, Giusy; Greco, Dario; Grenga, Lucia; Mantovani, Alberto; Muñoz, Amalia; Omeragic, Elma; Parissis, Nikolaos; Petrillo, Mauro; Saarimäki, Laura A; Soares, Helena; Sullivan, Kristie; Landesmann, Brigitte.
Afiliación
  • Clerbaux LA; European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
  • Albertini MC; Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy.
  • Amigó N; Biosfer Teslab SL., 43204 Reus, Spain.
  • Beronius A; Department of Basic Medical Sciences, Universitat Rovira i Virgili (URV), 23204 Reus, Spain.
  • Bezemer GFG; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
  • Coecke S; Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Daskalopoulos EP; Impact Station, 1223 JR Hilversum, The Netherlands.
  • Del Giudice G; Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.
  • Greco D; European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
  • Grenga L; European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
  • Mantovani A; Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland.
  • Muñoz A; Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland.
  • Omeragic E; Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SPI, F-30200 Bagnols-sur-Ceze, France.
  • Parissis N; Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
  • Petrillo M; European Commission, Joint Research Centre (JRC), 2440 Geel, Belgium.
  • Saarimäki LA; Faculty of Pharmacy, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.
  • Soares H; European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
  • Sullivan K; European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
  • Landesmann B; Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland.
J Clin Med ; 11(15)2022 Jul 31.
Article en En | MEDLINE | ID: mdl-35956081
Addressing factors modulating COVID-19 is crucial since abundant clinical evidence shows that outcomes are markedly heterogeneous between patients. This requires identifying the factors and understanding how they mechanistically influence COVID-19. Here, we describe how eleven selected factors (age, sex, genetic factors, lipid disorders, heart failure, gut dysbiosis, diet, vitamin D deficiency, air pollution and exposure to chemicals) influence COVID-19 by applying the Adverse Outcome Pathway (AOP), which is well-established in regulatory toxicology. This framework aims to model the sequence of events leading to an adverse health outcome. Several linear AOPs depicting pathways from the binding of the virus to ACE2 up to clinical outcomes observed in COVID-19 have been developed and integrated into a network offering a unique overview of the mechanisms underlying the disease. As SARS-CoV-2 infectibility and ACE2 activity are the major starting points and inflammatory response is central in the development of COVID-19, we evaluated how those eleven intrinsic and extrinsic factors modulate those processes impacting clinical outcomes. Applying this AOP-aligned approach enables the identification of current knowledge gaps orientating for further research and allows to propose biomarkers to identify of high-risk patients. This approach also facilitates expertise synergy from different disciplines to address public health issues.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza